Rapidly Acting Antidepressant
In the past decade, ketamine has shown to be a first in class rapidly acting medication for depression, showing effects in as early as 4 hours rather than 1 – 2 weeks like conventional antidepressants
What is Ketamir?
A Novel Oral Ketamine Analog
Ketamir-2 (“Ketamir”) is under investigation to potentially orally deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).
Superior Bioavailability
Oral bioavailability is predicted to be 80% based on a model of intestinal absorption and metabolism.
More Accessibility
Ketamir is being developed to potentially be delivered at home with appropriate conditions.
Analog
Its novel structure and properties are different from existing Ketamine.
Unscheduled
After making its scientific review of Ketamir, the DEA concluded that Ketamir-2 is not a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations.